Literature DB >> 27123798

Buprenorphine Prescribing: To Expand or Not to Expand.

Xiaofan Li1, Daryl Shorter, Thomas R Kosten.   

Abstract

As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27123798      PMCID: PMC4852384          DOI: 10.1097/PRA.0000000000000154

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  62 in total

1.  Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?

Authors:  Laxmaiah Manchikanti; Rajeev Manchukonda; Vidyasagar Pampati; Kim S Damron; Doris E Brandon; Kim A Cash; Carla D McManus
Journal:  Pain Physician       Date:  2006-04       Impact factor: 4.965

2.  The influence of prescription monitoring programs on chronic pain management.

Authors:  Jing Wang; Paul J Christo
Journal:  Pain Physician       Date:  2009 May-Jun       Impact factor: 4.965

3.  Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration.

Authors:  Adam J Gordon; Joseph Liberto; Stephanie Granda; Sara Salmon-Cox; Tykia Andree; Laura McNicholas
Journal:  Am J Addict       Date:  2008 Nov-Dec

4.  Intravenous buprenorphine self-administration by detoxified heroin abusers.

Authors:  Sandra D Comer; Eric D Collins; Marian W Fischman
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

5.  Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.

Authors:  Hannu Alho; David Sinclair; Erkki Vuori; Antti Holopainen
Journal:  Drug Alcohol Depend       Date:  2006-10-19       Impact factor: 4.492

6.  Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Kevin E O'Grady; Robert P Schwartz
Journal:  Am J Addict       Date:  2009 Sep-Oct

7.  Outcomes of buprenorphine maintenance in office-based practice.

Authors:  Stephen Magura; Stephen J Lee; Edwin A Salsitz; Andrew Kolodny; Susan D Whitley; Tanaquil Taubes; Randy Seewald; Herman Joseph; Deborah J Kayman; Chunki Fong; Lisa A Marsch; Andrew Rosenblum
Journal:  J Addict Dis       Date:  2007

8.  Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.

Authors:  Perrine Roux; Virgine Villes; Jerome Blanche; Didier Bry; Bruno Spire; Isabelle Feroni; M Patrizia Carrieri
Journal:  Drug Alcohol Depend       Date:  2008-05-13       Impact factor: 4.492

Review 9.  Why buprenorphine is so successful in treating opiate addiction in France.

Authors:  M Fatseas; Marc Auriacombe
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

10.  Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.

Authors:  David A Fiellin; Brent A Moore; Lynn E Sullivan; William C Becker; Michael V Pantalon; Marek C Chawarski; Declan T Barry; Patrick G O'Connor; Richard S Schottenfeld
Journal:  Am J Addict       Date:  2008 Mar-Apr
View more
  3 in total

1.  A New Tool to Tackle the Opioid Epidemic: Description, Utility, and Results from the Maine Diversion Alert Program.

Authors:  Brian J Piper; Clare E Desrosiers; Harriet C Fisher; Kenneth L McCall; Stephanie D Nichols
Journal:  Pharmacotherapy       Date:  2017-06-30       Impact factor: 4.705

2.  Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions.

Authors:  Abhishek Ghosh; Debasish Basu; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2018 Jul-Sep       Impact factor: 1.759

3.  Primary care for opioid use disorder.

Authors:  Paolo Mannelli; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2016-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.